Abstract Sessions begin at 1:00 PM. Join us in Hall 5 for Abstract Session 13 or Lomond Auditorium for Abstract Session 14. #IMS26

Etentamig-pom-dex, w/ etentamig administered once/4 weeks using a single step-up-dose & pom delayed to cycle2, shows “potentially class-leading CRS profile” deep responses in Kilimanjaro ph1b trial --- Cesar Rodriguez, MD #IMS26

BCMA×GPRC5D dual-targeted CAR-T therapy BMS-986453 showed >90% response rates at two dose levels in ongoing first-in-human early-phase trial, w/ 100% response 100% MRD-negativity in BCMA/GPRC5d-naïve pts --- Doris Hansen, MD #IMS26

Jing Li, MD, shares updated data for IBI3003, a novel BCMA×GPRC5d×CD3 trispecific antibody, in triple drug class-exposed pts with relapsed/refractory myeloma. ORR was 80%–85%, w/ 100% MRD-negativity, & efficacy also in pts w/ prior BCMA tx. #IMS26

Sonja Zweegman, MD, PhD, shared final MRD data from ph3 CEPHEUS trial w/ over 6-yr f/u. Dara-VRd continues to deepen responses & sustains MRD-negativity with improved PFS, supporting durable disease control. #IMS26

Industry Symposium contextualizes cure in myeloma around MRD testing, current evidence for long-term remission, potential for durable response with fixed-duration bispecific antibody-based therapies, & persistent access challenges. #IMS26

CAR-T, TCE, or ADC? Join the debate at 12:00 PM in Hall 5 as experts make the case for each drug class's role in the future of myeloma care. #IMS26

Abstract Sessions begin at 11:00 AM. Join us in Hall 5 for Abstract Session 11 or Lomond Auditorium for Abstract Session 12. #IMS26

Congratulations to the 2026 IMS Global Leadership Opportunity (GLO) Cohort at #IMS26.

Congratulations to this year's Young Investigator Award recipients at #IMS26.

Anna Baj, PhD student, shared data showing that NSD2, overexpressed in t(4;14) myeloma, mediates DNA methylation. Higher DNA methylation in NDS2-high, t(4;14) myeloma may also signal vulnerability to epigenetic modulatory agents. #IMS26

Jia Xu, PhD student, shares first-in-human data for QI-019A, a novel BCMA/CD19 bispecific in vivo CAR-T therapy in RRMM after ≥2 prior therapies. Absence of ≥grade 2 CRS, ICANS, severe AEs supports potential o/p administration, she said. #IMS26

Iberdomide-Dara-dex was the first approval in myeloma based on MRD-neg CR. Sagar Lonial, MD, who presented data from ph3 EXCALIBER-RRMM trial that supported the approval, said this combination is a new std of care in RRMM. #IMS26

PERSEUS 7-yr data confirm deep & durable benefit w/ Dara-VRd induction/consol + DaraR maint in transplant-eligible newly diagnosed myeloma. Pieter Sonneveld, MD, PhD, also shared data supporting MRD-guided Dara cessation during maintenance. #IMS26

Ph3 CERVINO findings show best-in-class safety profile for once-monthly etentamig, a novel BCMA x CD3 bispecific, and a reduced risk of death/progression by 60% vs std available treatments, in pts w/ RRMM ---Peter Voorhees, MD #IMS26

At 9:30 AM in Hall 5: Future Targets and New Modalities of Therapy. #IMS26

Abstract Sessions begin at 8:30 AM. Join us in Hall 5 for Abstract Session 9 or Lomond Auditorium for Abstract Session 10. #IMS26

Welcome to the final day of #IMS26. Join us for breakfast at 7:15 AM in Hall 5 during the Industry Symposium Supported by AbbVie, then explore today's educational sessions. View today's program: https://ow.ly/hi6650ZQtxs

Day 3 in Glasgow. More science, more connections, more progress. #IMS26

Read the recently updated Myeloma Collection, showcasing impactful articles published in Blood Cancer Discovery: buff.ly/CnLyN2M #IMS26